Recent Investment Analysts’ Ratings Updates for Thermo Fisher Scientific (TMO)

Several brokerages have updated their recommendations and price targets on shares of Thermo Fisher Scientific (NYSE: TMO) in the last few weeks:

• 10/28/2025 – Thermo Fisher Scientific had its price target raised by analysts at Morgan Stanley from $560.00 to $656.00. They now have an “overweight” rating on the stock.
• 10/25/2025 – Thermo Fisher Scientific was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 10/23/2025 – Thermo Fisher Scientific had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 10/23/2025 – Thermo Fisher Scientific had its price target raised by analysts at UBS Group AG from $500.00 to $590.00. They now have a “neutral” rating on the stock.
• 10/23/2025 – Thermo Fisher Scientific had its “buy” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
• 10/23/2025 – Thermo Fisher Scientific had its price target raised by analysts at TD Cowen from $612.00 to $654.00. They now have a “buy” rating on the stock.
• 10/23/2025 – Thermo Fisher Scientific had its price target raised by analysts at Wells Fargo & Company from $565.00 to $635.00. They now have an “overweight” rating on the stock.
• 10/23/2025 – Thermo Fisher Scientific had its price target raised by analysts at Barclays PLC from $585.00 to $625.00. They now have an “overweight” rating on the stock.
• 10/23/2025 – Thermo Fisher Scientific had its price target raised by analysts at Citigroup Inc. from $500.00 to $580.00. They now have a “neutral” rating on the stock.
• 10/22/2025 – Thermo Fisher Scientific had its price target raised by analysts at Leerink Partners from $545.00 to $580.00. They now have an “outperform” rating on the stock.
• 10/14/2025 – Thermo Fisher Scientific had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 10/12/2025 – Thermo Fisher Scientific was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 10/9/2025 – Thermo Fisher Scientific had its price target raised by analysts at JPMorgan Chase & Co. from $600.00 to $650.00. They now have an “overweight” rating on the stock.
• 10/8/2025 – Thermo Fisher Scientific was given a new $580.00 price target on by analysts at Redburn Partners.
• 10/7/2025 – Thermo Fisher Scientific had its price target raised by analysts at Evercore ISI from $525.00 to $590.00. They now have an “outperform” rating on the stock.
• 10/4/2025 – Thermo Fisher Scientific was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 10/2/2025 – Thermo Fisher Scientific had its price target raised by analysts at Barclays PLC from $550.00 to $585.00. They now have an “overweight” rating on the stock.
• 9/27/2025 – Thermo Fisher Scientific had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/11/2025 – Thermo Fisher Scientific was upgraded by analysts at Barclays PLC from an “equal weight” rating to an “overweight” rating. They now have a $550.00 price target on the stock, up previously from $490.00.
• 9/7/2025 – Thermo Fisher Scientific was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 9/2/2025 – Thermo Fisher Scientific was given a new $561.00 price target on by analysts at Royal Bank Of Canada. They now have an “outperform” rating on the stock.
• 8/30/2025 – Thermo Fisher Scientific was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 17,104 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $573.54, for a total value of $9,809,828.16. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at $65,247,057.48. This trade represents a 13.07% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 54,420 shares of company stock valued at $28,134,684. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.